{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:42:14Z","timestamp":1789152134656,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The effectiveness and safety of 48\u2009h intravenous 30\u2009\u03bcg\/kg\/day serelaxin infusion in acute heart failure (AHF) has been studied in six randomized, controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a fixed-effect meta-analysis including all studies of intravenous serelaxin initiated within the first 16\u2009h of admission for AHF. Endpoints considered were the primary and secondary endpoints examined in the serelaxin phase III studies. In six randomized controlled trials, 6105 total patients were randomized to receive intravenous serelaxin 30\u2009\u03bcg\/kg\/day and 5254 patients to control. Worsening heart failure to day 5 occurred in 6.0% and 8.1% of patients randomized to serelaxin and control, respectively (hazard ratio 0.77, 95% confidence interval 0.67\u20130.89; P = 0.0002). Serelaxin had no statistically significant effect on length of stay, or cardiovascular death, or heart or renal failure rehospitalization. Serelaxin administration resulted in statistically significant improvement in markers of renal function and reductions in both N-terminal pro-B-type natriuretic peptide and troponin. No significant adverse outcomes were noted with serelaxin. Through the last follow-up, which occurred at an average of 4.5 months (1\u20136 months), serelaxin administration was associated with a reduction in all-cause mortality, with an estimated hazard ratio of 0.87 (95% confidence interval 0.77\u20130.98; P = 0.0261).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of intravenous serelaxin to patients admitted for AHF was associated with a highly significant reduction in the risk of 5-day worsening heart failure and in changes in renal function markers, but not length of stay, or cardiovascular death, or heart or renal failure rehospitalization. Serelaxin administration was safe and associated with a significant reduction in all-cause mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1692","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T10:23:00Z","timestamp":1577701380000},"page":"315-329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effects of Serelaxin in Patients Admitted for Acute Heart Failure: A Meta-Analysis"],"prefix":"10.1093","volume":"22","author":[{"given":"John R.","family":"Teerlink","sequence":"first","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Davison","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Italian Association of Hospital Cardiologists (ANMCO) Research Center , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Cardiology and Intensive Care Unit, Nippon Medical School, Musashi-Kosugi Hospital , Kawasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[{"name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry H.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of California , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Heart Diseases, Medical University, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edwards","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Senger","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam L.","family":"Teichman","sequence":"additional","affiliation":[{"name":"Formerly Corthera , San Carlos, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav Wendelboe","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bispebjerg Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"2026011721335807000_ejhf1692-bib-0002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721335807000_ejhf1692-bib-0003","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"2026011721335807000_ejhf1692-bib-0004","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/ejhf.934","article-title":"RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research","volume":"19","author":"Cotter","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721335807000_ejhf1692-bib-0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur Heart J"},{"key":"2026011721335807000_ejhf1692-bib-0006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721335807000_ejhf1692-bib-0007","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00392-016-0979-8","article-title":"Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF","volume":"105","author":"Liu","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2026011721335807000_ejhf1692-bib-0008","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cardfail.2016.10.016","article-title":"Evaluating the efficacy, safety, and tolerability of serelaxin when added to standard therapy in Asian patients with acute heart failure: design and rationale of RELAX-AHF-ASIA trial","volume":"23","author":"Sato","year":"2017","journal-title":"J Card Fail"},{"key":"2026011721335807000_ejhf1692-bib-0009","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"2026011721335807000_ejhf1692-bib-0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2026011721335807000_ejhf1692-bib-0011","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011721335807000_ejhf1692-bib-0012","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1253\/circj.CJ-15-0227","article-title":"Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure","volume":"79","author":"Sato","year":"2015","journal-title":"Circ J"},{"key":"2026011721335807000_ejhf1692-bib-0013","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ejhf.1368","article-title":"Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU","volume":"21","author":"Maggioni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026011721335807000_ejhf1692-bib-0014","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cardfail.2018.11.007","article-title":"The efficacy, safety, and tolerability of additional serelaxin administration to standard therapy in Asian patients with acute heart therapy: the RELAX-AHF-ASIA trial","volume":"24","author":"Sato","year":"2018","journal-title":"J Card Fail"},{"key":"2026011721335807000_ejhf1692-bib-0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2026011721335807000_ejhf1692-bib-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"key":"2026011721335807000_ejhf1692-bib-0017","author":"Viechtbauer"},{"key":"2026011721335807000_ejhf1692-bib-0018","first-page":"295","volume-title":"The Handbook of Research Synthesis and Meta-Analysis","author":"Cooper","year":"2009","edition":"2nd ed."},{"key":"2026011721335807000_ejhf1692-bib-0019","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.12572","article-title":"Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study","volume":"79","author":"Kobalava","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026011721335807000_ejhf1692-bib-0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.433","article-title":"Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations","volume":"55","author":"Dahlke","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2026011721335807000_ejhf1692-bib-0021"},{"key":"2026011721335807000_ejhf1692-bib-0022","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.cardfail.2016.06.051","article-title":"RELAX-REPEAT: a multicenter, prospective, randomized, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure","volume":"22","author":"Teerlink","year":"2016","journal-title":"J Card Fail"},{"key":"2026011721335807000_ejhf1692-bib-0023"},{"key":"2026011721335807000_ejhf1692-bib-0024","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCHEARTFAILURE.114.001536","article-title":"Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study","volume":"7","author":"Voors","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721335807000_ejhf1692-bib-0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J Card Fail"},{"key":"2026011721335807000_ejhf1692-bib-0026","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1749-6632.2008.03819.x","article-title":"First clinical experience with intravenous recombinant human relaxin in compensated heart failure","volume":"1160","author":"Dschietzig","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"2026011721335807000_ejhf1692-bib-0027"},{"key":"2026011721335807000_ejhf1692-bib-0028"},{"key":"2026011721335807000_ejhf1692-bib-0029"},{"key":"2026011721335807000_ejhf1692-bib-0030"},{"key":"2026011721335807000_ejhf1692-bib-0031"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/2\/315\/66112728\/eurjhf_22_2_315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/2\/315\/66112728\/eurjhf_22_2_315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:34:44Z","timestamp":1768703684000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/2\/315\/8385356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,30]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1692","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"2019-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}